Daniel Pelak, chief executive officer at Closure Medical that was acquired recently by Johnson & Johnson, is taking over as the CEO of startup Interventional Rhythm Management (IRM).

Pelak will assume his new job on Sept. 26. He leaves Closure in early September, according to IRM.

IRM is focused on treatment of abnormal heart rhythms and is based in RTP.

“The technology that exists within IRM will revolutionize how we treat cardiac patients with a potential rhythm disorder,” Pelak said. “This technology, once successfully commercialized, will save thousands of lives each year by offering therapy to patients who need a defibrillator but are not receiving one.”

Pelak worked 26 years with medical device firm Medtronic before joining Closure.

IRM, which was launched in 2003, has raised $35.2 million in venture capital.